Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255409 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT02255409 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 607 participants.
The verdict
NCT02255409, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118\_05
Interventions
- BIOLOGICAL Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
- BIOLOGICAL non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255409
The ClinicalTrials.gov registry entry for NCT02255409 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) is the first listed.
NCT02255409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255409 about?
NCT02255409 is a clinical study titled "Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05". Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118\_05
What is the current status of trial NCT02255409?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2014-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02255409?
The interventions under investigation include: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) (BIOLOGICAL), non-adjuvanted Quadrivalent Influenza Vaccine (QIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02255409?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.